DBV Technologies (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Monday, April 2nd.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
A number of other research analysts have also commented on DBVT. BidaskClub lowered DBV Technologies from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 6th. Citigroup set a $57.00 target price on DBV Technologies and gave the stock a “buy” rating in a report on Wednesday, February 14th. HC Wainwright reissued a “buy” rating on shares of DBV Technologies in a report on Thursday, March 15th. Finally, Deutsche Bank set a $33.00 target price on DBV Technologies and gave the stock a “buy” rating in a report on Tuesday, March 27th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $46.00.
Shares of DBV Technologies stock traded down $0.13 on Monday, reaching $23.98. 68,847 shares of the company were exchanged, compared to its average volume of 298,873. DBV Technologies has a one year low of $20.08 and a one year high of $50.57. The stock has a market cap of $1,336.92, a P/E ratio of -9.34 and a beta of 0.97. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 0.01.
Hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new position in shares of DBV Technologies in the third quarter valued at approximately $132,000. Commonwealth Equity Services Inc purchased a new position in shares of DBV Technologies in the third quarter valued at $233,000. Belpointe Asset Management LLC purchased a new position in shares of DBV Technologies in the third quarter valued at $343,000. Geode Capital Management LLC grew its position in shares of DBV Technologies by 20.2% in the fourth quarter. Geode Capital Management LLC now owns 20,833 shares of the company’s stock valued at $512,000 after purchasing an additional 3,499 shares in the last quarter. Finally, Highbridge Capital Management LLC purchased a new position in shares of DBV Technologies in the third quarter valued at $1,061,000. Institutional investors and hedge funds own 39.51% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally published by Macon Daily and is the sole property of of Macon Daily. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://macondaily.com/2018/04/17/zacks-investment-research-lowers-dbv-technologies-dbvt-to-hold-updated-updated.html.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Get a free copy of the Zacks research report on DBV Technologies (DBVT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.